AB
AbbVie
ABBV · NYSE
$256.37 -1.48% (-$3.84)
1M +6.70%
Market Cap $459.9B
P/E Ratio 72.84x
Div. Yield 2.62%
ROE -
Bulios Fair Price
$181.8
29.1% downside
Current Price
$256.37
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ABBV is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
9/9Valuation
21 /100
Expensive EV/EBITDA 24.68x
P/S 7.14x
P/FCF 23.37x
Growth
11 /100
Declining Rev. growth 1.75%
FCF growth 9.76%
EPS growth 29.03%
Profitability
93 /100
Strong Net margin 9.81%
Op. margin 29.32%
FCF margin 30.57%
Quality
60 /100
Average ROA 4.67%
Asset turnover 0.48x
ROIC 13.46%
Debt
41 /100
Moderate Int. coverage 4.57x
Net debt/EBITDA 3.03x
Current ratio 0.81x
Stability
70 /100
Stable Rev. volatility 7.66%
EPS volatility 30.83%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ABBV
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert A. Michael
Employees
57,000
Headquarters
North Chicago
Upcoming events
30 OCT
Earnings
Upcoming earnings report